Trius Therapeutics
A biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections.
Launch date
Employees
Market cap
-
Enterprise valuation
€110—165m (Dealroom.co estimates Jun 2011.)
San Diego California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Early VC | ||
$20.0m | Series A | ||
| N/A | $19.2m | Debt | |
| N/A | N/A | IPO | |
| N/A | $30.2m | Early VC | |
* | N/A | $29.9m | Post IPO Equity |
$705m | Acquisition | ||
| Total Funding | €45.6m | ||
Related Content
Recent News about Trius Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.